Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature

Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID‐19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Bishawi, Ahmad, Abdel Hadi, Hamad, Elmekaty, Eman, Al Samawi, Musaed, Nair, Arun, Abou Kamar, Mohammed, Al Maslamani, Muna, Abdelmajid, Alaaeldin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867201/
https://www.ncbi.nlm.nih.gov/pubmed/35228879
http://dx.doi.org/10.1002/ccr3.5467
_version_ 1784656003337289728
author Al Bishawi, Ahmad
Abdel Hadi, Hamad
Elmekaty, Eman
Al Samawi, Musaed
Nair, Arun
Abou Kamar, Mohammed
Al Maslamani, Muna
Abdelmajid, Alaaeldin
author_facet Al Bishawi, Ahmad
Abdel Hadi, Hamad
Elmekaty, Eman
Al Samawi, Musaed
Nair, Arun
Abou Kamar, Mohammed
Al Maslamani, Muna
Abdelmajid, Alaaeldin
author_sort Al Bishawi, Ahmad
collection PubMed
description Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID‐19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such patient groups is important to assess for future safety.
format Online
Article
Text
id pubmed-8867201
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-88672012022-02-27 Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature Al Bishawi, Ahmad Abdel Hadi, Hamad Elmekaty, Eman Al Samawi, Musaed Nair, Arun Abou Kamar, Mohammed Al Maslamani, Muna Abdelmajid, Alaaeldin Clin Case Rep Case Reports Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID‐19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such patient groups is important to assess for future safety. John Wiley and Sons Inc. 2022-02-24 /pmc/articles/PMC8867201/ /pubmed/35228879 http://dx.doi.org/10.1002/ccr3.5467 Text en © 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Al Bishawi, Ahmad
Abdel Hadi, Hamad
Elmekaty, Eman
Al Samawi, Musaed
Nair, Arun
Abou Kamar, Mohammed
Al Maslamani, Muna
Abdelmajid, Alaaeldin
Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature
title Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature
title_full Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature
title_fullStr Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature
title_full_unstemmed Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature
title_short Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature
title_sort remdesivir for covid‐19 pneumonia in patients with severe chronic kidney disease: a case series and review of the literature
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867201/
https://www.ncbi.nlm.nih.gov/pubmed/35228879
http://dx.doi.org/10.1002/ccr3.5467
work_keys_str_mv AT albishawiahmad remdesivirforcovid19pneumoniainpatientswithseverechronickidneydiseaseacaseseriesandreviewoftheliterature
AT abdelhadihamad remdesivirforcovid19pneumoniainpatientswithseverechronickidneydiseaseacaseseriesandreviewoftheliterature
AT elmekatyeman remdesivirforcovid19pneumoniainpatientswithseverechronickidneydiseaseacaseseriesandreviewoftheliterature
AT alsamawimusaed remdesivirforcovid19pneumoniainpatientswithseverechronickidneydiseaseacaseseriesandreviewoftheliterature
AT nairarun remdesivirforcovid19pneumoniainpatientswithseverechronickidneydiseaseacaseseriesandreviewoftheliterature
AT aboukamarmohammed remdesivirforcovid19pneumoniainpatientswithseverechronickidneydiseaseacaseseriesandreviewoftheliterature
AT almaslamanimuna remdesivirforcovid19pneumoniainpatientswithseverechronickidneydiseaseacaseseriesandreviewoftheliterature
AT abdelmajidalaaeldin remdesivirforcovid19pneumoniainpatientswithseverechronickidneydiseaseacaseseriesandreviewoftheliterature

Ejemplares similares